HAB Pharmaceuticals & Research Limited (HAB Pharma), an Indian pharmaceutical company with a legacy spanning over four decades, has appointed Pankaj Agarwal as Chief Financial Officer (CFO).
The appointment comes as HAB Pharma strengthens its financial and organisational capabilities to support its next phase of growth, driven by expanding manufacturing capacities, R&D initiatives, domestic presence and international market opportunities.
A Chartered Accountant with almost 18 years of experience across the healthcare and pharmaceutical sectors, Pankaj brings expertise in financial strategy, planning and forecasting, financial reporting and compliance, fundraising, treasury management, audit, risk assessment and operational efficiency.
Prior to joining HAB Pharma, he held senior finance roles at Innovcare Lifesciences, Max Healthcare and Vyome Biosciences. At Innovcare, he contributed to a US$5 million Series C fundraise and a further US$1 million through non-convertible debentures and led the implementation of SAP for the accounts function. He began his career in audit and compliance with PricewaterhouseCoopers (PwC) and later worked as a Partner at Lahoti Roy & Associates.
At HAB Pharma, Pankaj oversees financial planning, budgeting, reporting, compliance, risk management and corporate governance, while providing financial insights to support informed business decisions. He works closely with the leadership team to strengthen financial discipline, operational efficiency and sustainable value creation across the organisation.
He is a Chartered Accountant and holds a Post Graduate Executive Management Programme in Finance and Sales from SPJIMR, Mumbai.
Commenting on the appointment, Saurabh Agarwal, CEO and Director, HAB Pharma, said “Since joining HAB Pharma in February, Pankaj has brought a strong focus on financial discipline, structured planning and informed decision-making. His understanding of finance, compliance and business operations has been valuable as the company continues to strengthen its manufacturing capabilities, R&D initiatives and market presence. We are confident that his continued contribution will support HAB Pharma’s growth ambitions and help build a stronger financial and governance framework for the organisation.”
Pankaj Agarwal, Chief Financial Officer, HAB Pharma, said, “Over the past six months at HAB Pharma, it has been an enriching experience to work closely with the leadership team and gain a deeper understanding of the company’s business, operations and growth priorities. The organisation is at an important stage of its evolution, with significant opportunities across manufacturing, R&D, exports and domestic markets. I look forward to continuing to strengthen financial processes, improve operational efficiency and support disciplined and sustainable growth.”
The appointment marks another step in HAB Pharma’s ongoing organisational strengthening as the company expands its manufacturing footprint, advances its product and R&D pipeline, and builds its presence across domestic and international markets.